subglobal1 link | subglobal1 link | subglobal1 link | subglobal1 link | subglobal1 link | subglobal1 link | subglobal1 link
subglobal2 link | subglobal2 link | subglobal2 link | subglobal2 link | subglobal2 link | subglobal2 link | subglobal2 link
subglobal3 link | subglobal3 link | subglobal3 link | subglobal3 link | subglobal3 link | subglobal3 link | subglobal3 link
subglobal4 link | subglobal4 link | subglobal4 link | subglobal4 link | subglobal4 link | subglobal4 link | subglobal4 link
subglobal5 link | subglobal5 link | subglobal5 link | subglobal5 link | subglobal5 link | subglobal5 link | subglobal5 link
subglobal6 link | subglobal6 link | subglobal6 link | subglobal6 link | subglobal6 link | subglobal6 link | subglobal6 link
subglobal7 link | subglobal7 link | subglobal7 link | subglobal7 link | subglobal7 link | subglobal7 link | subglobal7 link
subglobal8 link | subglobal8 link | subglobal8 link | subglobal8 link | subglobal8 link | subglobal8 link | subglobal8 link

Courtesy: CDC/ Dr. Ray Butler; Janice Carr


Tuberculosis

  • TB claims 1.5-2 million every year
  • One third of the world population is infected with M. tuberculosis
  • More than 90% of infected adults will never develop disease, 40-50% of the infected infants will develop disease
  • It is still not fully understood why some individuals develop active disease, whereas most apparently control the infection by an appropriate immune response
  • Vaccination with BCG does not protect from pulmonary TB


Hypothesis


Genetically controlled interactions between mycobacteria and host cells that are regulated by the host innate and adaptive immune responses dictate the outcome of mycobacterial infection.

HOMITB aims to expand our knowledge of the interactions between the immune system and the infection causing disease in individuals infected with M. tuberculosis.


 

 



 

 


 

 

Home || Contact Us | ©2009 John.sennett@ki.se